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Abstract: Objective: Vaccines are effective in controlling and eradicating infectious diseases. However,
adverse events following immunization (AEFI) can occur in susceptible individuals. The objective
of this study was to analyze the Brazilian AEFI database and compare eight vaccines in order to
profile risks of AEFIs related to the mandated pediatric schedule of immunization, considering the
age and sex of the child, type of vaccine, and reported adverse events. Methods: We analyzed the
Brazilian AEFI database integrating reports between 2005 and 2010 for children less than 10-years old
immunized with eight mandated vaccines: diphtheria, pertussis, tetanus, Haemophilus influenzae type
b (TETRA); diphtheria, tetanus, and pertussis (DTP); Bacillus Calmette–Guerin (BCG); oral poliovirus
vaccine (OPV); measles, mumps, and rubella (MMR); oral rotavirus vaccine (ORV); hepatitis B
(HB); and yellow fever (YF). We compared the children’s age regarding types of AEFI, evaluated
AEFI factors associated with the chance of hospitalization of the child, and estimated the chance of
notification of an AEFI as a function of the type of vaccine. In total, 47,105 AEFIs were observed for
the mandated vaccines. Results: The highest AEFI rate was for the TETRA vaccine and the lowest
was for the OPV vaccine, with 60.1 and 2.3 events per 100,000 inoculations, respectively. The TETRA
vaccine showed the highest rate of hypotonic hyporesponsive episode, followed by convulsion and
fever. The MMR and YF vaccines were associated with generalized rash. BCG was associated with
enlarged lymph glands but showed the largest negative (protective) association with hyporesponsive
events and seizures. Compared with children aged 5–9-years old, young children (<1 year) showed
significantly higher odds of hospitalization. Conclusions: The Brazilian AEFI registry is useful to
compare the magnitude and certain characteristics of adverse events associated with mandated
pediatric vaccines.
Keywords: vaccine; adverse event; immunization; AEFI; passive surveillance
1. Introduction
Public health policies to control and eradicate infectious diseases depend on the immunization
success of specific vaccines. In many parts of the world where medical resources and health
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infrastructure are lacking, vaccines are a cost-effective public-health intervention [1]. In fact, they
are even more cost-effective in monetary terms in rich countries where the expensive treatment of
infectious diseases is prevented, freeing up health care resources for purposes other than treating
preventable diseases. Furthermore, immunization policies have enabled important achievements in
public health, such as the eradication and/or control of yellow fever, smallpox, and poliomyelitis [1].
The protocol to register and/or license vaccines is rigidly controlled in order to achieve and to
ensure their safety and effectiveness. Nevertheless, after a vaccine is licensed, susceptible individuals
can react to vaccine ingredients (antigens and other constituents in the formulation). Most reactions
to vaccines are reported as discomfort, induration at the site of the inoculation, and pain [2]. These
occurrences after vaccination are mild and resolve themselves; severe events following vaccination are
relatively rare [2]. However, a vaccine surveillance and follow-up system is crucial to monitor issues
related to adverse events following immunization (AEFI) [3]. These AEFI systems, as summarized
by Zhou et al. [4], are important to “(1) detect new, unusual, or rare vaccine adverse events;
(2) monitor increases in known adverse events; (3) determine patient risk factors for particular types of
adverse events; (4) identify vaccine lots with increased numbers or types of reported adverse events;
and (5) assess the safety of newly licensed vaccines”.
Despite a stringent safety protocol during development, vaccines, like any pharmaceutical
product, carry risks. Because of size, clinical trials during vaccine development are not suitable
for capturing rare or deferred adverse events/effects [5]. Therefore, essential monitoring of temporal
associations between vaccination and the occurrence of serious, mild adverse, or unexpected reactions
to vaccination depend on such systems. Infrastructure for reporting AEFIs is in place in many countries,
including Brazil [6]. However, these systems and/or appropriate infrastructure are absent in most
developing countries, thus leaving the neediest populations without an AEFI vigilance system.
As discussed by Waldman et al. [7], concerns about the safety of vaccines while maintaining high
levels of immunization coverage have led countries (with different health care structures) to implement
surveillance systems to monitor adverse events postvaccination. These passive surveillance systems
are characterized by the capture of spontaneous notification, thus constituting the simplest way of
analyzing adverse events.
Because vaccines are administered to large cohorts of healthy children (infants and small children),
it is crucial to monitor the burden of AEFIs. Brazil has a successful immunization program, and in 1998,
created the systems of vigilance for adverse postvaccination events (SVEAPV) nationwide. In Brazil,
AEFIs are collected through the SVEAPV, which can minimize some deficiencies by consistently
identifying the type of vaccine, dose, and the subject. We analyzed this database to compare eight
vaccines from the mandated pediatric schedule of immunization in order to profile risks of AEFIs
related to the age and sex of the child, type of vaccine, and reported adverse events.
2. Materials and Methods
This is a descriptive study analyzing the frequency and distribution of the most common AEFI
reported in children from 2005 to 2013. The study was approved by the Ethics Committee of the Federal
University of Brasilia (UnB CAAE #41787215.5.0000.0030) and consisted of an analysis of the data
collected in AEFIs captured by all Brazilian states through the National Immunization Program (PNI).
In this study, the data were presented collectively in order to safeguard the integrity and anonymity
of all those involved (patients and health care agents). The results were used only for the purpose of
the statistical study and not as evidence for or against a specified vaccine. Adverse events here were
used to mean “any moderate or severe and/or unexpected adverse sign or symptom occurring after
vaccination” [7].
The AEFI database is organized by the Central Office of the PNI after receiving structured
information in a standardized form. These data are digitalized and electronically sent to the
pharmacovigilance office of the PNI. A detailed account of how the Brazilian AEFI works is provided
in Waldman et al. [7] and Monteiro et al. [8].
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The database, during the period of 2005–2010, contained the number of AEFIs for children aged
less than 10-years old who received any of the eight vaccines available in all public-run (federal,
state, or municipal) hospitals or equally public-run health centers throughout the country, free of
charge. In parallel, a strong private medical sector provides vaccinations with a cost. Thus, pediatric
patients have optional access to private-run hospitals and vaccination clinics which are not bound to
report AEFIs.
Most of the recommended vaccines, around 90%, are produced in Brazil [9]. Monteiro et al. [8]
have described in detail the passive Brazilian AEFI system. It receives reports prepared by specialized
personnel (nurses or physicians) on a regular basis from hospitals, primary health care units, and
vaccination clinics throughout the country. The AEFI reports are filled out using a specific form that
captures demographic data, dates of vaccination and reported AEFIs, characteristics of the adverse
event (type, severity, treatment, and length of hospital stay, whether in- or outpatient), maintenance of
the vaccination schedule, as well as the manufacturer of the vaccine and the respective lot number.
Monteiro et al. [8] also informed that the completeness of these data ranges from 70.0% to 90.0%, with
a trend toward increasing completeness.
Only the events related to a single inoculation were used to summarize the 10 most frequent
AEFIs in order to analyze the association between the chosen events and vaccines and to analyze the
differences between vaccines regarding the distribution of children’s age. With this approach, we
guaranteed that there was no other vaccine causing the adverse reaction under consideration. The total
number of adverse events reported after the application of one or more vaccines was used to model
the likelihood of hospitalization after the specific AEFI.
In this study, the following vaccines were considered: diphtheria, pertussis, tetanus, meningitis,
and other infections caused by Haemophilus influenzae type b (TETRA) (three doses); diphtheria, tetanus,
and pertussis (DTP) (two doses); Bacillus Calmette–Guerin (BCG) (one dose); oral poliovirus vaccine
(OPV) (three doses plus the “booster” shot); measles, mumps, and rubella (MMR) (two doses); oral
rotavirus vaccine against diarrhea (ORV) (two doses); hepatitis B (HB) (three doses); and yellow fever
(YF) (only one dose every 10 years). Only two of these vaccines (ORV and OPV) are administered
orally, while the remaining six vaccines are given through injections. In 2005, the estimated Brazilian
population aged less than 10-years old numbered 35,809,635. The vaccine coverage in Brazil ranged
from 81% to 85% of children aged 18 months in the very low to medium high socioeconomic classes [10].
Individuals aged 10 or over and those without age recorded were excluded. Because of convenience
and availability, only the years from 2005 to 2010 were analyzed.
In the statistical analysis, we considered the following variables (and respective categories) for any
child with a reported AEFI: age of child (<1-year old; 1–4-years old; 5–9-years old (reference group);
sex (boys and girls as the reference group); regions by state (27); year of report (2005–2010); vaccine
type (DTP, BCG, OPV, MMR, ORV, HB, and YF; TETRA is the reference vaccine); AEFI (73 reported
types); hospitalization (yes or no used as the reference groups); vaccine dose (first dose, second dose,
and third dose; first booster and second booster as the reference groups).
Statistical Analysis
For the adjustments of the database and all the statistical analyses considered in this work, we used
the free software R (see the R-project in https://www.r-project.org). We considered the chi-squared
and Kruskal–Wallis hypothesis tests and adjusted residuals together with the Dunn hypothesis test
(package pgirmess) for multiple comparisons. We also used this software for both the unconditional and
correlated logistic regression analyses. The correlated logistic regression, also known as generalized
estimating equations (GEE), was run with the gee R-package.
The homogeneity chi-squared hypothesis test was used to obtain the statistical significance
between eight independent vaccine types related to the 73 reported AEFI types (H1_0: there was
homogeneity among vaccine types as to the AEFI distribution). The analysis of the adjusted residuals is
recommended whenever the null hypothesis H1_0 is rejected. The Kruskal–Wallis hypothesis test was
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used to decide if there was any difference among the eight independent vaccine types related to the
age of any child who suffered any reported AEFI (H2_0: there was no difference among the ages of children
in all eight vaccine types). When the null Kruskal–Wallis hypothesis test was rejected, we used the Dunn
hypothesis test for a multiple comparison analysis. The methodology for all hypothesis tests is found
elsewhere [11,12].
To investigate the association between the hospitalization rate and the reported AEFI in a child,
we considered the logistic regression analysis: the effect of p independent random variables X over a
dichotomous dependent random variable Y (Y = 1, meaning that a hospitalization event occurs while
Y = 0 means that no hospitalization event occurs). In the logistic regression analysis, we used both
the univariate and multivariate schemes. In the univariate case, we analyzed the odds ratio of the
hospitalization groups based on a reference category for each variable, while in the multivariate case,
we used the same analysis but now took into account the effects of all other variables.
We also considered both the uncorrelated and correlated data. The analytic approach used for
modeling the outcome variables that had dichotomous correlated responses was the generalized
estimating equations (GEE). This method took into account the correlated nature of the responses.
We refer the reader to Hosmer and Lemeshow [13] and Kleinbaum and Klein [14] for the logistic
regression analysis.
3. Results
A total of 47,105 AEFIs records captured by the Brazilian National Immunization System were
analyzed and recorded according to single or multiple inoculations on a given visit during the studied
period of 2005–2010. This total pertained to records of patients that needed medical attention after an
AEFI (first or second notification). Overall descriptive results are summarized in Tables 1–3 by age and
type of vaccine.
Table 1. Total of adverse postvaccination events considering single inoculation (SI) and combined
inoculation (CI) with other vaccines in the same visit.
Vaccine
Total of Adverse Events
SI CI SI/CI (%)
TETRA 30315 32362 93.7
DTP 6405 6840 93.6
BCG 3501 3595 97.4
MMR 1284 1567 81.9
HB 934 1513 61.7
YF 886 1009 87.8
ORV 700 1620 43.2
OPV 407 1881 21.6
TETRA: diphtheria, pertussis, tetanus, Haemophilus influenzae type b; DTP: diphtheria, tetanus, pertussis; BCG:
Bacillus Calmette–Guerin; MMR: measles, mumps, rubella; HB: hepatitis B; YF: yellow fever; ORV: oral vaccine
against rotavirus diarrhea; OPV: oral poliovirus vaccine.
Table 2. Frequency of occurrence of the 10 most reported adverse events related to the injectable
vaccines by age groups, considering only single inoculation doses.
Event
Age (Years)
<1 1–4 5–9 Total
N % N % N % N %
HB
Abscess hot spot 218 29.18 1 0.13 0 0 219 29.32
Pain, redness and heat 107 14.32 4 0.54 4 0.54 115 15.39
Induration 72 9.64 3 0.4 0 0 75 10.04
Fever ≥ 39.5 ◦C 69 9.24 1 0.13 0 0 70 9.37
Other severe events 58 7.76 1 0.13 0 0 59 7.9
HR after 2 h 51 6.83 0 0 1 0.13 52 6.96
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Table 2. Cont.
Event
Age (Years)
<1 1–4 5–9 Total
N % N % N % N %
Fever < 39.5 ◦C 49 6.56 2 0.27 0 0 51 6.83
Generalized rash 38 5.09 2 0.27 1 0.13 41 5.49
Lump 31 4.15 2 0.27 0 0 33 4.42
Other local reactions 26 3.48 4 0.54 2 0.27 32 4.28
Total 719 96.25 20 2.68 8 1.07 747 100
TETRA
HHE 8294 30.32 783 2.86 38 0.14 9115 33.32
Fever ≥ 39.5 ◦C 4589 16.77 539 1.97 23 0.08 5151 18.83
Fever < 39.5 ◦C 3270 11.95 196 0.72 7 0.03 3473 12.7
Pain, redness, and heat 2559 9.35 179 0.65 14 0.05 2752 10.06
Febrile convulsion 2067 7.56 415 1.52 18 0.07 2500 9.14
Induration 993 3.63 59 0.22 3 0.01 1055 3.86
Other severe events 962 3.52 90 0.33 1 0 1053 3.85
Afebrile seizure 687 2.51 97 0.35 7 0.03 791 2.89
Lump 707 2.58 36 0.13 2 0.01 745 2.72
Generalized rash 648 2.37 69 0.25 5 0.02 722 2.64
Total 24,776 90.57 2463 9 118 0.43 27,357 100
DTP
Pain, redness, and heat 53 0.97 816 14.87 438 7.98 1307 23.81
Fever 61 1.11 652 11.88 185 3.37 898 16.36
HHE 82 1.49 564 10.28 157 2.86 803 14.63
Fever < 39.5 ◦C 42 0.77 506 9.22 152 2.77 700 12.75
Febrile convulsion 36 0.66 458 8.34 95 1.73 589 10.73
Induration 16 0.29 234 4.26 73 1.33 323 5.88
Lump 10 0.18 152 2.77 39 0.71 201 3.66
Abscess hot spot 9 0.16 179 3.26 62 1.13 250 4.55
Difficulty walking 6 0.11 180 3.28 52 0.95 238 4.34
Headache and vomiting 6 0.11 124 2.26 50 0.91 180 3.28
Total 321 5.85 3865 70.41 1303 23.74 5489 100
BCG
Lymphadenopathy 758 23.53 18 0.56 12 0.37 788 24.46
Abscess hot spot 368 11.42 36 1.12 76 2.36 480 14.9
Cold abscess site 382 11.86 62 1.92 23 0.71 467 14.49
Ulcer > 1 cm 276 8.57 29 0.9 42 1.3 347 10.77
Lymphadenitis > 3 cm 332 10.3 4 0.12 5 0.16 341 10.58
Lump 208 6.46 19 0.59 5 0.16 232 7.2
Suppurated lymphadenitis 214 6.64 11 0.34 1 0.03 226 7.01
Lymphadenopathy > 3 cm 132 4.1 8 0.25 2 0.06 142 4.41
Pain, redness, and heat 91 2.82 3 0.09 9 0.28 103 3.2
Other local reactions 85 2.64 4 0.12 7 0.22 96 2.98
Total 2846 88.33 194 6.02 182 5.65 3222 100
MMR
Generalized rash 44 3.95 399 35.82 19 1.71 462 41.47
Fever < 39.5 ◦C 17 1.53 149 13.38 11 0.99 177 15.89
Fever ≥ 39.5 ◦C 9 0.81 142 12.75 5 0.45 156 14
HR after 2 h 5 0.45 84 7.54 3 0.27 92 8.26
HR up to 2 h 1 0.09 30 2.69 5 0.45 36 3.23
Pain, redness, and heat 5 0.45 37 3.32 22 1.97 64 5.75
Other severe events 5 0.45 31 2.78 4 0.36 40 3.59
Febrile convulsion 4 0.36 28 2.51 1 0.09 33 2.96
Mumps 1 0.09 25 2.24 6 0.54 32 2.87
Headache and vomiting 1 0.09 17 1.53 4 0.36 22 1.97
Total 92 8.26 942 84.56 80 7.18 1114 100
YF
Generalized rash 140 19.31 32 4.41 5 0.69 177 24.41
HR up to 2 h 95 13.1 19 2.62 5 0.69 119 16.41
HR after 2 h 84 11.59 27 3.72 2 0.28 113 15.59
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Table 2. Cont.
Event
Age (Years)
<1 1–4 5–9 Total
N % N % N % N %
Fever ≥ 39.5 ◦C 59 8.14 24 3.31 5 0.69 88 12.14
Fever < 39.5 ◦C 44 6.07 23 3.17 7 0.97 74 10.21
Other severe events 34 4.69 5 0.69 3 0.41 42 5.79
Pain, redness, and heat 27 3.72 5 0.69 3 0.41 35 4.83
Meningitis 5 0.69 9 1.24 16 2.21 30 4.14
Headache 7 0.97 4 0.55 13 1.79 24 3.31
Headache and vomiting 15 2.07 5 0.69 3 0.41 23 3.17
Total 510 70.34 153 21.1 62 8.55 725 100
TETRA: diphtheria, pertussis, tetanus, Haemophilus influenzae type b; DTP: diphtheria, tetanus, pertussis; BCG:
Bacillus Calmette–Guerin; HB: hepatitis B; HHE: hypotonic hyporesponsive episode; HR: hypersensibility reaction;
MMR: measles, mumps, rubella; YF: yellow fever.
Table 3. Frequency of occurrence of the 10 most reported adverse events related to the oral vaccines by
age groups, considering only single inoculation doses.
Event
Age (Years)
< 1 4-Jan 9-May Total
N % N % N % N %
OPV (Oral poliovirus)
Other severe events 31 9.78 30 9.46 0 0 61 19.24
Generalized rash 21 6.62 28 8.83 1 0.32 50 15.77
Fever ≥ 39.5 ◦C 13 4.1 25 7.89 0 0 38 11.99
Fever < 39.5 ◦C 13 4.1 25 7.89 0 0 38 11.99
HR up to 2 h 15 4.73 17 5.36 0 0 32 10.09
HR after 2 h 12 3.79 24 7.57 1 0.32 37 11.67
HHE 12 3.79 3 0.95 0 0 15 4.73
Other local reactions 7 2.21 7 2.21 0 0 14 4.42
Febrile convulsion 4 1.26 10 3.15 0 0 14 4.42
Headache and vomiting 3 0.95 15 4.73 0 0 18 5.68
Total 131 41.32 184 58.04 2 0.63 317 100
ORV (Oral rotavirus)
Other severe events 329 48.24 3 0.44 0 0 332 48.68
Intussusception 173 25.37 3 0.44 1 0.15 177 25.95
Other local reactions 43 6.3 1 0.15 1 0.15 45 6.6
Fever ≥ 39.5 ◦C 35 5.13 0 0 0 0 35 5.13
Headache and vomiting 33 4.84 1 0.15 0 0 34 4.99
Fever < 39.5 ◦C 32 4.69 0 0 0 0 32 4.69
HR after 2 h 9 1.32 0 0 0 0 9 1.32
Generalized rash 7 1.03 0 0 0 0 7 1.03
Angioedema 7 1.03 0 0 0 0 7 1.03
HHE 4 0.59 0 0 0 0 4 0.59
Total 672 98.53 8 1.17 2 0.29 682 100
TETRA: diphtheria, pertussis, tetanus, Haemophilus influenzae type b; DTP: diphtheria, tetanus, pertussis; BCG:
Bacillus Calmette–Guerin; HB: hepatitis B; HHE: hypotonic hyporesponsive episode; HR: hypersensibility reaction;
MMR: measles, mumps, rubella; YF: yellow fever.
Table 1 shows the total number of AEFIs associated with the eight studied vaccines. Additionally,
when more than one mandated vaccine was applied on the same visit, there were AEFIs for the specified
vaccine. A total of 36,953 adverse cases were associated with 36,742 children. Therefore, 211 adverse
events were associated with children who had already experienced AEFIs (second notification) from
a previous immunization. For each notification, more than one adverse event could have occurred.
Therefore, there was an average of 1.28 AEFIs per child. The ratio of single and combined inoculations
(SI/CI in Table 1) shows the proportion of adverse events attributed to a single vaccine as a function of
the total AEFI reported for that vaccine.
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The frequencies of the 10 most reported AEFIs are presented in Tables 2 and 3 as injectable
and oral vaccines, respectively. Table 2 summarizes AEFIs for injected vaccines by age groups. The
10 most reported events corresponded to 90.24% (27,357) of the total. For all injectable vaccines, the
most reported adverse event was hypotonic hyporesponsive episode (HHE), accounting for 33.32%
(9115) of all the AEFIs, and it occurred mainly in the inactivated vaccines (TETRA and DTP). The
tetravalent vaccine presented the highest number of notifications among the injectable vaccines, with
30,315 events occurring after a single application. For the TETRA vaccine, the age range “less than
1-year old” accounted for 90.57% (24,776) of the 10 most reported events (see Table 2). For the DTP
vaccine, the 10 most reported AEFIs accounted for 87.70% (5489) of the total. Among them, “pain,
redness, and warmth” (local reaction) accounted for 23.81% (1307) of the events (Table 2). The most
frequent DTP-related AEFI usually occurred in age class “1–4-years old”, with 70.41% (3865) of the
events. The AEFIs associated with HB vaccine corresponded to 79.98% (747) of the total number
of events reported, and “hot spot abscess” was the most reported adverse event, with 28.32% (219).
The HB-related AEFIs occurred mostly in children younger than 1-year old, with 96.25% (719) of all
notifications (Table 2).
Among the live attenuated vaccines (BCG, MMR, YF), AEFIs after BCG corresponded to 92%
(3222) of the total. The most commonly reported AEFI was “nonsuppurative lymphadenopathy”, with
24.46% (788) of the events. The most frequent BCG-related AEFI occurred mostly in children younger
than 1-year old, comprising 72.16% (2846) of the notifications. The BCG vaccine was responsible
for 3501 adverse events after a single application, with 97.4% of all reactions possibly associated
with it (Table 1). AEFIs occurring with the MMR vaccine corresponded to 86.7% (1114) of the total
reported events. The most reported adverse event for this vaccine was “generalized rash”, with 41.47%
(462) of the events. The MMR-AEFI occurred mostly in children in the group “1–4 years-old”, with
84.56% (942) of the notifications. For the application of the YF vaccine alone, the 10 most frequent
events corresponded to 81.83% (725) of all notifications. According to Table 2, the most prevalent
was “generalized rash”, with 24.41% (177) of the adverse events. Most YF-related AEFIs occurred in
children younger than 1 year of age, corresponding to 70.34 % (510) of the total notifications.
The AEFIs related to the oral vaccines (OPV and ORV) are shown in Table 3. Overall, the oral
vaccines showed the lowest rate of AEFIs, that is, 43.2% and 21.6%, respectively (Table 1).
However, for the ORV vaccine alone, the event with the highest number of notifications was
“other serious or unusual events”, with 48.68% (332) of the total, followed by “intussusception”, with
25.95% (177) of total notifications (Table 3). The AEFIs occurred mostly in children younger than 1 year
of age, corresponding to 98.53% (672) of the total events (Table 3).
Overall, most of the reported AEFIs (75%) occurred in children less than 1 year of age (35,393),
followed by children in the age group between 1 and 4 years of age (9555). Older children in the age
group of 5–9 years of age showed the lowest number of cases (2157). However, the median age for
AEFI varied according to vaccines, reflecting the recommended immunization calendar as follows:
DTP (19 months), OPV (16 months), MMR (13 months), YF (10 months), TETRA (5 months), ORV
(4 months), BCG (3 months), and HB (2 months). As a function of the total number of doses of vaccine,
the rate of AEFIs varied from 60.1 (TETRA) to 2.3 (OPV) per 100,000 doses, as illustrated in Figure 1.
Based on the adjusted residuals, it is possible to note the most significant associations. After a
homogeneity chi-squared hypothesis test, Appendix A Table A1 shows the adjusted residuals for the
estimates of the association between vaccines and AEFIs. Table A1 shows that among the 10 most
reported adverse events, the most significant positive association occurred between the TETRA vaccine
and HHE, with fever without convulsions and afebrile and febrile convulsion events. Regarding the
other featured events, the vaccines MMR and YF were significantly associated with a generalized
rash event. The BCG vaccine showed the largest negative association (protective) with HHE event,
with an adjusted residual of −37.6, while the BCG vaccine’s largest positive association occurred with
increased lymph nodes, with an adjusted residual of 80.2.
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Figure 1. Estimated rate of AEFI per 100,000 doses in children younger than 10-years old, between
2005 and 2010 considering single and combined inoculations (TETRA: diphtheria, pertussis, tetanus,
Haemophilus influenzae type b; DTP: diphtheria, tetanus, pertussis; BCG: Bacillus Calmette–Guerin;
MMR: measles, mumps, rubella; HB: hepatitis B; YF: yellow fever).
The Kruskal–Wallis hypothesis test showed that there is statistically significant evidence that
the median age of affected children is different for at least one vaccine. The results of a multiple
comparison Dunn hypothesis test are shown in Appendix A Table A2. At a 5% significance level,
the DTP vaccine had a significantly higher median age than all the other vaccines when considering
affected children with some kind of AEFI after a single inoculation. The HB vaccine showed the
highest association, with AEFI in children with the lowest median age, that is, two months. The OPV,
MMR, and YF vaccines showed no significant differences. Likewise, the test showed no significant
differences between ORV and BCG vaccines where the median ages were, respectively, four and three
months. AEFI events after the TETRA vaccine inoculation occurred in children with a median age of
five months old, which is significantly higher than the median age for ORV, BCG, and HB vaccines.
When considering both the univariate and multivariate schemes, the odds ratio of hospitalization
analyzed by the unconditional and correlated logistic regression showed similar results for 95%
confidence intervals. Appendix A Table A3 presents the odds ratio (OR) of hospitalization due to an
AEFI only for the correlated logistic regression analysis. Significance in the odds of hospitalization
was seen for age classes. Younger children (1–4 years and less than 1 year of age) had higher odds of
hospitalization than children 5–9 years of age, and these differences were significant in the univariate
model (OR = 1.5 for the first two age classes, while OR = 1.0 for the oldest age class).
When considering the full model accounting for gender, vaccine types, and doses, the difference
was no longer significant between children younger than 1 year and between 5 and 9 years (OR = 1.1).
Compared with the TETRA vaccine, the YF and ORV vaccines showed higher odds of hospitalization
(with or without other factors in the full model, OR = 1.8 and 1.5, respectively). For the DPT and BCG
vaccines (OR = 0.8 and 0.7, respectively), a decrease in the chance of hospitalization was observed,
when compared to TETRA. When comparing the vaccine doses, adverse events that occurred after
the second booster dose had a chance of hospitalization that was significantly lower than for the first
booster and third, second, and first doses.
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4. Discussion
This study profiled the most reported AEFIs in Brazilian children (according to the national
registry of adverse events) related to the mandated pediatric vaccines. In Brazil, AEFI surveillance is
mandatory and administered by the Ministry of Health. In this study, vaccines were presented as oral
and injectable in order to better understand the nature of the Brazilian AEFI. Despite high regional
diversity in the rate of AEFIs, the vaccine with the highest reported prevalence of adverse effects were
those that were injected (TETRA > DTP > BCG > MMR > YF). The lowest AEFI prevalence was noted
for the oral vaccines (ORV > OPV). The AEFI and its prevalence rate depended on the vaccine and age
of the child. Because vaccine exposure is skewed towards early age, AEFIs for some vaccines seemed
to have a higher incidence in young children.
The differences in age of AEFI varied according to the vaccine. Therefore, the early AEFIs
(registered for HB) were considered mild. The percentage of febrile adverse events varied with age for
almost all vaccines (Tables 2 and 3). The percentage of vaccine-induced febrile seizures diminished with
age, and these were highest at the age of <1 year and lowest in the 4–9-year-old group. Age-associated
outcomes of fever and febrile convulsion were seen for vaccination with HB and TETRA, respectively.
Injectable vaccines (TETRA, DTP, BCG, MMR, YF) showed a distinct AEFI pattern when compared
with oral administered vaccines (Table 1). During infancy, breastfeeding can influence vaccine
response [15] and it may or may not affect the incidence of adverse behavior, local reactions, and
fever [16]. The AEFIs related to the TETRA vaccine in Brazil have been discussed by Monteiro et al. [8].
They found them higher than in other countries and attributed them to the case definition adopted in
Brazil which downplays mild events and late onset AEFIs. This probably results in an overestimation
of the severe events [8].
Our results concurred with those of the study by Monteiro et al. [8] on DTP between the years of
2002 to 2005. Also, Alguacil-Ramos et al. [17] reported that diphtheria, tetanus, and acellular pertussis
(DTaP) had the highest AEFI reported in Spanish children (96.6/100,000 doses). Gkampeta et al. [18]
reviewed the association of vaccines with an elevated risk of febrile events. They pointed to seizures
after DTP and MMR among the most frequently cited adverse vaccine events in the literature. They
suggested a lower risk of seizures with DTP vaccination in the first 2–4 months of life. It seems that
the MMR vaccination is not associated with occurrence of seizures in the first year of life. However,
delayed vaccination post 15 months is associated with more postvaccination seizures [18].
Thomas et al. [19] reviewed the AEFIs associated with YF vaccines and reported no cases in
children and infants in active surveillance studies. In passive surveillance studies, there was a very
low rate of adverse events for the general population (0.51 AEFI/million doses). Specific neurological
adverse events extracted from this database from 2007 to 2012 have been reported for YF in Brazil [20].
The highest rate of neurological adverse events (0.83 per 100,000 doses) was in the age group from 5 to
9 years.
The relationship between rotavirus vaccine and intussusceptions is known for early vaccines that
were withdrawn from the market. Nevertheless, studies from Australia and the United States have
shown that new rotavirus vaccines still carry a significant increased risk of intussusception [21]. Indeed,
Patel et al. [22] showed that the rotavirus vaccine could have caused additional cases of intussusception
in Mexico (approximately 1 per 51,000 infants) and Brazil (approximately 1 per 68,000 infants) per year.
Moylett and Henderson [23] discussed the mechanistic actions of the risks of vaccine
administration associated with adverse events—those occurring in the acute setting (like AEFIs)
and those related to risk of developing medical conditions in the future [23]. Vaccines are formulated
to contain preservatives (Thimerosal) and adjuvants (aluminum), which carry neurotoxic risks and/or
unintended immune reactions [24] that can manifest over months or years. In this context, nonspecific
effects of vaccines have been gaining traction. Indeed, in most studies, Thimerosal-containing vaccines
have shown a high risk of developing tic disorders or contact dermatitis [24]. The current AEFI system
does not recognize any of these chronic conditions that may result from or be associated with pediatric
vaccines [24].
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In certain populations, vaccines can have an opposing nonspecific effect; therefore, interactions
of vaccines and AEFI may become a topic of investigation. Goldman and Miller [25] analyzed the
Vaccine Adverse Event Reporting System database (of the United States) and suggested a positive
correlation between the number of vaccine doses and the rate of hospitalizations and deaths. Vaccine
(DTaP/Haemophilus influenzae b) associated adverse events (occurring between 2002 and 2005) that
evolved to death were 0.2%, as reported by Monteiro et al. [9].
Whitaker et al. [26] reviewed vaccines’ adverse effects taking into consideration “adversomics” as
a new paradigm to understand vaccine safety. While such approaches represent the cutting edge of
integrative sciences (immunogenomics and system biology), they do not preclude ecological studies
of different populations in postvaccine licensure. Indeed, we do not yet have a system suited to
understand/capture AEFIs according to the type of vaccine (live attenuated, inactivated whole cell,
adjuvanted, monovalent, polyvalent, etc.) or that profiles children’s individual biology.
The limitations of this study mainly appeared due to issues inherent to vaccine adverse events
reporting systems. These issues have been discussed elsewhere [27] and apply to the present work.
This type of surveillance used in this study is low cost and simple; however, it has the disadvantage
of being less sensitive, so it is more vulnerable to subnotification. Therefore, a passive surveillance
system carries less representation and presents difficulties in the standardization of case definitions [7].
Summing up, this kind of system is subject to: (a) bias (underreporting of common mild adverse
events); (b) quality and completeness of reporting; and (c) reporting efficiency. However, in our case,
all the AEFIs reported had confirmation—they all required medical attention and/or hospitalization.
Long-lasting effects or disabling illness caused by or associated with the reported AEFI were not
followed by the system after the medical visit or hospitalization had taken place. Although the AEFIs
were clearly perceived as harmful or needing medical attention, in cases with death as the outcome,
the confirmation has to go through a detailed and complex medical procedure that hardly ever gets
reported in the Brazilian AEFI. It is also noteworthy that there are no compensation programs in place
to assist victims of AEFI. When an AEFI leads to an injury, Brazilian families bear the burden. Cases
taken to court are few and concentrated in the most developed parts of the country; furthermore,
judicial decisions, when compared, involve contradictory sentences for similar cases [28].
5. Conclusions
Due to the large size of the country and the variety of vaccine brands used, it was beyond the
purpose of this study to establish the relative safety of any specific vaccine. However, the Brazilian
AEFI system is useful to monitor and manage the safety of the pediatric vaccination program. When
used properly, this registry is useful to compare the magnitude and certain characteristics of adverse
events associated with the mandated pediatric vaccines. In the present case, it is worth mentioning a
high association of the TETRA vaccine with hypotonic hyporesponsive episode and febrile convulsion.
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Appendix A
Table A1. Adjusted residuals analysis for association estimates between vaccines and the 10 most
reported adverse events (considering only single inoculation doses).
AEFI
Vaccine
TETRA DTP BCG OPV MMR ORV HB YF p
Test 1 <0.0001
HHE
Yes 9115(38.5%)
803
(16.6%)
1
0.00%
15
(4.4%)
14
(1.4%)
4
−0.60%
30
(3.9%)
10
(1.4%)
[60.4] [−19.5] [−37.6] [−9.9] [−19.1] [−15.8] [−15.2] [−16.1]
No 14,580(61.5%)
4037
(83.4%)
3252
(100.0%)
327
(95.6%)
975
(98.6%)
643
(99.4%)
740
(96.1%)
699
(98.6%)
[−60.4] [19.5] [37.6] [9.9] [19.1] [15.8] [15.2] [16.1]
Total 23,695(100.0%)
4840
(100.0%)
3253
(100.0%)
342
(100.0%)
989
(100.0%)
647
(100.0%)
770
(100.0%)
709
(100.0%)
Test 2 <0.0001
Afebrile seizure 2724(11.5%)
599
(12.4%)
0
0.00%
18
(5.3%)
34
(3.4%)
4
−0.60%
23
(3.0%)
13
(1.8%)
[16.4] [6.8] [−19.6] [−2.8] [−6.7] [−7.9] [−6.4] [−7.1]
Febrile
convulsion
562
(2.4%)
92
(1.9%)
0
0.00%
1
−0.30%
7
−0.70%
2
−0.30%
5
−0.60%
7
−1.00%
[8.9] [−0.1] [−8.4] [−2.2] [−2.8] [−3.0] [−2.6] [−1.8]
Fever without
seizure
8040
(33.9%)
1502
(31.0%)
44
(1.4%)
74
(21.6%)
326
(33.0%)
65
(10.0%)
116
(15.1%)
155
(21.9%)
[27.4] [2.9] [−36.7] [−3.1] [2.6] [−10.9] [−8.8] [−4.4]
Cases without 12,369(52.2%)
2647
(54.7%)
3209
(98.6%)
249
(72.8%)
622
(62.9%)
576
(89.0%)
626
(81.3%)
534
(75.3%)
fever or
convulsion [−37.8] [−6.7] [48.1] [5.2] [2.5] [15.6] [12.7] [8.9]
Total 23,695(100.0%)
4840
(100.0%)
3253
(100.0%)
342
(100.0%)
989
(100.0%)
647
(100.0%)
770
(100.0%)
709
(100.0%)
Test 3 <0.0001
Generalized rash
Yes 722(3.0%)
112
(2.3%)
7
−0.20%
50
(14.6%)
462
(46.7%)
7
−1.10%
41
(5.3%)
177
(25.0%)
[−18.6] [−7.8] [−12.3] [9.1] [65.1] [−4.2] [1.1] [26.6]
No 22,973(97.0%)
4728
(97.7%)
3246
(99.8%)
292
(85.4%)
527
(53.3%)
640
(98.9%)
729
(94.7%)
532
(75.0%)
[18.6] [7.8] [12.3] [−9.1] [−65.1] [4.2] [−1.1] [−26.6]
Total 23,695(100.0%)
4840
(100.0%)
3253
(100.0%)
342
(100.0%)
989
(100.0%)
647
(100.0%)
770
(100.0%)
709
(100.0%)
Test 4 <0.0001
Increased lymph
nodes
Yes 1079(4.6%)
345
(7.1%)
1513
(46.5%)
4
(1.2%)
38
(3.8%)
0
0.00%
82
(10.6%)
10
(1.4%)
[−39.7] [−4.2] [80.2] [−5.0] [−5.5] [−7.9] [1.9] [−7.0]
No 22,616(95.4%)
4495
(92.9%)
1740
(53.5%)
338
(98.8%)
951
(96.2%)
647
(100.0%)
688
(89.4%)
699
(98.6%)
[39.7] [4.2] [−80.2] [5.0] [5.5] [7.9] [−1.9] [7.0]
Total 23,695(100.0%)
4840
(100.0%)
3253
(100.0%)
342
(100.0%)
989
(100.0%)
647
(100.0%)
770
(100.0%)
709
(100.0%)
Note: The value between brackets [] corresponds to the adjusted residuals.
Table A2. Results of multiple comparisons of vaccines for median age (in months) of affected children
with the 10 most reported adverse events using the Dunn hypothesis test, considering only single
inoculation doses.
Vaccine Median Age (in Months) Homogeneous Groups *
DTP 19 A
OPV 16 B
MMR 13 B
YF 10 B
Int. J. Environ. Res. Public Health 2018, 15, 1149 12 of 13
Table A2. Cont.
Vaccine Median Age (in Months) Homogeneous Groups *
TETRA 5 C
ORV 4 D
BCG 3 D
HB 2 E
Note: * Different letters represent significantly different medians (α = 0.05).
Table A3. Odds ratio (OR) of hospitalization for adverse postvaccination cases and the 95% confidence
interval in the univariate and multivariate models using the studied predictors, considering a logistic
regression model for correlated data (GEE) for single inoculation doses.
Predictor Univariate Multivariate
OR IC 95% OR IC 95%
Gender
Female 1 - 1 -
Male 1.0 (0.99; 1.08) 1.0 (0.99; 1.08)
Age
5–9 years 1 - 1 -
1–4 years 1.5 (1.38; 1.71) 1.2 (1.09; 1.39)
<1 year 1.5 (1.35; 1.65) 1.1 (0.98; 1.27)
Vaccine
TETRA 1 - 1 -
DTP 0.8 (0.76; 0.86) 0.8 (0.69; 0.89)
BCG 0.7 (0.65; 0.76) 0.7 (0.67; 0.79)
OPV 1.1 (0.91; 1.43) 1.3 (0.99; 1.63)
MMR 1.0 (0.84; 1.08) 0.9 (0.79; 1.07)
ORV 1.8 (1.48; 2.11) 1.8 (1.52; 2.16)
HB 1.0 (0.90; 1.21) 1.1 (0.91; 1.22)
YF 1.4 (1.21; 1.68) 1.5 (1.25; 1.74)
Applied Dosage
2nd booster 1 - 1 -
1st booster 1.5 (1.37; 1.73) 1.5 (1.31; 1.70)
3rd dose 1.7 (1.52; 1.88) 1.4 (1.19; 1.62)
2nd dose 1.6 (1.42; 1.74) 1.3 (1.13; 1.52)
1st dose 1.5 (1.33; 1.61) 1.3 (1.09; 1.46)
TETRA: diphtheria, pertussis, tetanus, Haemophilus influenzae type b; DTP: diphtheria, tetanus, pertussis; BCG:
Bacillus Calmette–Guerin; MMR: measles, mumps, rubella; HB: hepatitis B; YF: yellow fever.
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